CN1288373A - 脂质混合物以及含该脂质混合物的磷脂悬浮物的制备 - Google Patents

脂质混合物以及含该脂质混合物的磷脂悬浮物的制备 Download PDF

Info

Publication number
CN1288373A
CN1288373A CN99802102A CN99802102A CN1288373A CN 1288373 A CN1288373 A CN 1288373A CN 99802102 A CN99802102 A CN 99802102A CN 99802102 A CN99802102 A CN 99802102A CN 1288373 A CN1288373 A CN 1288373A
Authority
CN
China
Prior art keywords
lipid
mixture
float
nonaqueous solvent
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN99802102A
Other languages
English (en)
Other versions
CN1191822C (zh
Inventor
P·K·许
J·E·比肖普
小E·S·马德里加
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Publication of CN1288373A publication Critical patent/CN1288373A/zh
Application granted granted Critical
Publication of CN1191822C publication Critical patent/CN1191822C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/226—Solutes, emulsions, suspensions, dispersions, semi-solid forms, e.g. hydrogels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Acoustics & Sound (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明描述了制备脂质混合物和含该脂质混合物的均匀可过滤的磷脂悬浮物的方法,该悬浮物可用作超声造影剂。

Description

脂质混合物以及含该脂质混合物的磷脂悬浮物的制备
发明领域
本发明一般涉及脂质混合物以及含该脂质混合物的均匀可过滤磷脂悬浮物的制备方法，这种悬浮物可用作超声造影剂。
发明背景
磷脂造影剂的生产可以分为以下步骤：(1)制备脂质混合物；(2)混匀所述本体溶液(bulk solution)，包括脂质混合物在基本水介质中水合和分散产生脂质悬浮物；(3)经除菌过滤器过滤所述本体溶液从而使得所述悬浮物不含微生物污染物；(4)在受控无菌区将所述无菌悬浮物分配装入各个管制瓶中；(5)把所分装的管制瓶载入冷冻干燥器室以用全氟丙烷气(PFP)替代管制瓶上部气体；(6)将气体交换后密封的管制瓶转移至高压灭菌器以进行最后的灭菌。在该方法中有三个主要障碍：(1)所述脂质混合物的均匀性；(2)所述脂质混合物的水合作用；(3)所述悬殊浮物的均匀性和颗粒大小；以及(4)所述悬浮物经除菌过滤器无菌过滤。
通常将需要的脂质溶解或悬浮于合适的水溶剂或非水溶剂体系中，然后经冷冻或蒸馏减少体积，从而生产磷脂混合物。理想的是，该方法生产高度的含量均匀性和高纯度的混合固体物。然而，尽管在小的实验室规模可较好实施，但是该简单方法一旦扩大到生产规模的量时常常是有问题的。难点包括：(1)在溶剂去除步骤中保持含量的均匀性(由于不同溶解度引起的)；(2)保持纯度(当使用水时由于水解副反应引起的常见问题)；(3)提高纯度；(4)最小化溶剂体积；和(5)回收最后的固体(例如从大反应器刮出固体不是可行的)。
生产脂质混合物后，最后的混合通常包括把所述混合物加入水介质中。因为磷脂是疏水性的并难溶于水，所以磷脂或脂质混合物直接加入水溶液中引起所述脂质粉聚合形成非常难以分散的团块。因此，所述水合作用过程不能控制在合理的过程时间范围内。磷脂或脂质混合物在水介质中的直接水合作用产生颗粒范围0.6μm-100μm的混浊悬浮液。由于较大的颗粒大小分布，所以当所述悬浮液温度低于脂质的凝胶到液晶(gel-to-liquid crystal)的相变温度时，所述悬浮液不能在室温下过滤。所述脂质将累积在过滤器中，导致流速受限，在大多数情况下，不久所述过滤器就完全阻塞。通过常规的分批法，即使用常规使用的船舶式螺旋桨(marine propeller)在温度升高(例如40℃-80℃)下延长混合时间(例如6小时)后，也不能获得所述悬浮物颗粒大小的进一步减小。
尽管在温度升高即高于脂质的相变温度的情况下过滤是可能的，但是当使用正常过滤压时，仍然要除去大量的较大的脂质颗粒。所述无菌过滤物的浓缩在批与批文间同样有不同的脂质含量，脂质含量取决于所述脂质开始时如何进行水合的，而其水合作用又由所述原料的物理特征例如形态学所决定。
直接水合所述脂质或脂质混合物以产生均匀悬浮物和经除菌过滤器过滤所述悬浮物的方法可能是困难的，并且放大到任何合理的工业规模例如＞20L的成本高昂。
因此，目前要求保护的生产脂质混合物以及随后的磷脂悬浮物的方法，目的是通过提供切实可行的方法解决上述问题，该方法容易放大并可用于各种生产设备而不需要大改变或定制现有设备。
发明概述
因此，本发明的目的之一是提供一种制备脂质混合物的新方法。
本发明的另一目的是提供一种制备得自所述脂质混合物的磷脂悬浮物的新方法。
本发明人的发现已经实现了这些目的以及其它目的，这些目的在以下详细说明书中将变得显而易见，所述发现是在加入水溶液前将脂质混合物溶解于合适非水溶剂中使得可以生产磷脂悬浮物。
发明详述
[1]因此，在第一个实施方案中，本发明提供一种制备磷脂悬浮物的新方法，包括：
(1)使脂质混合物与非水溶剂接触，由此使得所述脂质混合物基本上溶解于所述非水溶剂中；以及，
(2)使步骤(1)的溶液与水溶液接触形成脂质悬浮物。
[2]在一个优选的实施方案中，所述非水溶剂选自丙二醇、乙二醇和聚乙二醇300。
[3]在一个更优选的实施方案中，所述非水溶剂是丙二醇。
[4]在另一优选的实施方案中，所述脂质混合物包括：
(a)1,2-二棕榈酰基-sn-甘油基-3-磷脂酰胆碱；
(b)1,2-二棕榈酰基-sn-甘油基-3-磷脂酸一钠盐；和，
(c)N-(甲氧基聚乙二醇5000氨基甲酰基)-1,2-二棕榈酰基-sn-甘油基-3-磷脂酰乙醇胺一钠盐。
[5]在另一优选的实施方案中，在步骤(1)中，所述非水溶剂在与所述脂质混合物接触前加热至温度约30-70℃。
[6]在另一更优选的实施方案中，所述非水溶剂在与所述脂质混合物接触前加热至温度约50-55℃。
[7]在另一优选的实施方案中，脂质混合物与非水溶剂的比率为从每mL非水溶剂含脂质混合物约5mg至约15mg/mL。
[8]在另一更优选的实施方案中，脂质混合物与非水溶剂的比率为约10mg/mL。
[9]在另一优选的实施方案中，在步骤(2)中，所述水溶液选自水、盐水、盐水/甘油混合物和盐水/甘油/非水溶剂混合物。
[10]在另一更优选的实施方案中，所述水溶液是盐水和甘油的混合物。
[11]在另一更优选的实施方案中，所述水溶液是盐水、甘油和丙二醇的混合物。
[12]在另一更优选的实施方案中，存在氯化钠6.8mg/mL、存在甘油0.1mL/mL、存在丙二醇0.1mL/mL以及存在所述脂质混合物约0.75-1.0mg/mL。
[13]在甚至更优选的实施方案中，存在脂质混合物0.75mg/mL。
[14]在另一更优选的实施方案中，存在脂质混合物1.0mg/mL。
[15]在另一优选的实施方案中，在步骤(2)中，所述水溶液在与步骤(1)的溶液接触前加热至温度约45-60℃。
[16]在另一更优选的实施方案中，所述水溶液在与步骤(1)的溶液接触前加热至温度约50-55℃。
[17]在另一优选的实施方案中，所述方法还包括：
(3)加热步骤(2)的脂质悬浮物至温度约等于或高于存在于所述悬浮物中的脂质的凝胶到液晶的最高相变温度。
[18]在另一更优选的实施方案中，在步骤(3)中，所述脂质悬浮物加热至温度至少约67℃。
[19]在另一更优选的实施方案中，所述方法还包括：
(4)经除菌过滤器过滤所述脂质悬浮物。
[20]在另一甚至更优选的实施方案中，在步骤(4)中，用两个除菌过滤柱进行过滤。
[21]在另一更优选的实施方案中，在步骤(4)中，所述除菌过滤柱的温度从约70℃至80℃。
[22]在另一还优选的实施方案中，在步骤(4)中使用0.2μm亲水性滤膜。
[23]在另一甚至更优选的实施方案中，所述方法还包括：
(5)将步骤(4)的过滤溶液分配装入管制瓶中。
[24]在另一更优选的实施方案中，所述方法还包括：
(6)用全氟烃气交换步骤(5)的管制瓶上部的气体。
[25]在另一甚至更优选的实施方案中，所述全氟烃气是全氟丙烷。
[26]在另一甚至更优选的实施方案中，用冷冻室进行上部气体的交换。
[27]在另一甚至更优选的实施方案中，所述方法还包括：
(7)灭菌步骤(6)的管制瓶。
[28]在甚至更优选的实施方案中，在步骤(7)中，所述管制瓶于约126-130℃灭菌1-10分钟。
[29]在第二个实施方案中，本发明提供一种制备脂质混合物的新方法，包括：
(a)使至少两种脂质与第一种非水溶剂接触；
(b)浓缩所述溶液成为稠密的凝胶；
(c)使所述稠密凝胶与第二种非水溶剂接触；以及，
(d)收集所得的固体物。
[30]在一个优选的实施方案中，在步骤(a)中，所述脂质是：
(ⅰ)1,2-二棕榈酰基-sn-甘油基-3-磷脂酰胆碱；
(ⅱ)1,2-二棕榈酰基-sn-甘油基-3-磷脂酸一钠盐；和，
(ⅲ)N-(甲氧基聚乙二醇5000氨基甲酰基)-1,2-二棕榈酰基-sn-甘油基-3-磷脂酰乙醇胺一钠盐。
[31]在另一优选的实施方案中，在步骤(a)中，第一种非水溶剂是乙醇和甲苯的混合物。
[32]在另一优选的实施方案中，在步骤(c)中，第二种非水溶剂是甲基叔丁基醚。
[33]在另一优选的实施方案中，在步骤(a)中，所述溶液加热至足以使所述脂质完全溶解入所述溶剂中的温度。
[34]在另一更优选的实施方案中，在步骤(a)中，所述溶液加热至约25-75℃。
[35]在另一优选的实施方案中，在步骤(d)，所收集的固体物用甲基叔丁基醚洗涤并真空干燥。
[36]在第三个实施方案中，本发明提供一种新的磷脂悬浮物，它包括：
(a)悬浮物的脂质混合物量约0.75-1.0mg/mL。
(b)悬浮物的氯化钠量约6.8mg/mL。
(c)悬浮物的甘油量约0.1mL/mL。
(d)悬浮物的丙二醇量约0.1mL/mL；和
(e)水；
其中所述悬浮物用所述方法制备，该方法包括：
(1)使脂质混合物与非水溶剂接触，由此使得所述脂质混合物基本上溶解于非水溶剂中；
(2)使步骤(1)溶液与水溶液接触形成脂质悬浮物；
(3)加热步骤(2)的脂质悬浮物至温度约等于或高于存在于所述悬浮物中的脂质的凝胶到液晶的最高相变温度。
(4)经除菌过滤器过滤所述脂质悬浮物。
[37]在另一优选的实施方案中，所述脂质混合物包含：
(a)1,2-二棕榈酰基-sn-甘油基-3-磷脂酰胆碱；
(b)1,2-二棕榈酰基-sn-甘油基-3-磷脂酸一钠盐；和，
(c)N-(甲氧基聚乙二醇5000氨基甲酰基)-1,2-二棕榈酰基-sn-甘油基-3-磷脂酰乙醇胺一钠盐。
[38]在另一更优选的实施方案中，所述非水溶剂在与所述脂质混合物接触前加热至温度约50-55℃。
[39]在另一更优选的实施方案中，脂质混合物与非水溶剂的比率约10mg/mL。
[40]在另一更优选的实施方案中，所述水溶液是盐水、甘油和丙二醇的混合物。
[41]在一个甚至更优选的实施方案中，存在脂质混合物0.75mg/mL。
[42]在另一更优选的实施方案中，所述水溶剂在与步骤(1)的溶液接触前加热至温度约50-55℃。
[43]在另一更优选的实施方案中，在步骤(3)中，所述脂质悬浮物加热至至少约67℃。
[44]在另一更优选的实施方案中，在步骤(4)中，使用二个0.2μm亲水性滤膜。
配方
打算从至少数克规模、一公斤规模、数公斤规模或工业规模实施本发明。作为本文所用的数克规模最好是其中至少一种原料物质以10g或10g以上、更优选至少50g或50g以上、甚至更优选至少100g或100g以上存在的规模。作为本文所用的数公斤规模是指其中使用至少一种原料物质为一公斤以上的规模。作为本文所用的工业规模是指非实验室规模并且足以供应足够用于临床试验或分销给消费者的产品的规模。
作为本文所用的脂质混合物或磷脂混合物是指已经混合的两种或两种以上的脂质。所述脂质混合物一般为粉末形式。最好是至少一种脂质是磷脂。所述脂质混合物最好含有1,2-二棕榈酰基-sn-甘油基-3-磷脂酰胆碱(DPPC)、1,2-二棕榈酰基-sn-甘油基-3-磷脂酸一钠盐(DPPA)和N-(甲氧基聚乙二醇5000氨基甲酰基)-1,2-二棕榈酰基-sn-甘油基-3-磷脂酰乙醇胺一钠盐(MPEG5000-DPPE)。存在于所述混合物的各种脂质的量将取决于所需要的最终产品。各种脂质的优选比率描述于实施例部分。在本发明方法中可以使用种类繁多的其它脂质，例如描述于Unger等的美国专利第5,469,854号中的脂质，该专利内容通过引用结合到本文中。
作为本文所用的磷脂是含一个油性(疏水的)烃链和一个极性(亲水的)磷首基的脂肪物质。磷脂类是两亲的。它们在水介质中自然形成界面和密闭小泡。磷脂构成动物细胞浆膜物质的约50％。
脂质混合物的制备
所述脂质混合物可以通过水悬浮物-冷冻干燥法或使用有机溶剂的有机溶剂溶解-沉淀法制备。在水悬浮物-冷冻干燥法中，所需要的脂质悬浮于温度升高的水中，然后经冷冻干燥浓缩。最好使用溶解法。步骤(a)：
所述有机溶剂溶解-沉淀法包括使需要的脂质(例如DPPA、DPPC和MPEG5000 DPPE)与第一种非水溶剂系统接触。该系统通常是溶剂的组合物，例如CHCl3/MeOH,CH2Cl2/MeOH和甲苯/MeOH。第一种非水溶剂系统最好是甲苯和甲醇的混合物。最好是加热所述脂质溶液至足以达到完全溶解的温度。该温度最好为约25-75℃，更优选约35-65℃。
溶解后，需要通过热过滤或冷却至室温后过滤除去不需要的外来物质。可以使用已知的过滤方法(例如重力过滤、真空过滤或压力过滤)。步骤(b)：
然后浓缩所述溶液至稠密凝胶/半固体。最好是经真空蒸馏进行浓缩。也可以使用其它方法，例如旋转蒸发浓缩该溶液。该步骤的温度最好为约20-60℃，更优选30-50℃。步骤(c)：
然后将所述稠密凝胶/半固体分散于第二种非水溶剂。最好在接近室温(例如15-30℃)下，使该混合物淤浆化。有用的第二种非水溶剂是使得所述脂质从过滤溶液沉淀的非水溶剂。第二种非水溶剂最好是甲基叔丁基醚(MTBE)。可以使用其它醚类和醇类。
步骤(d)：
然后收集在加入第二种非水溶剂后产生的固体物。所收集的固体物最好用另一部分的第二种非水溶剂(例如MTBE)洗涤。最好是在室温下通过真空过滤或离心进行收集。收集后，最好是所述固体物于温度约20-60℃下真空干燥。
相对于所述水悬浮物/冷冻干燥法，优选使用有机溶剂溶解-沉淀法，原因如下：
(1)因为所述脂质易溶于甲苯/甲醇，所以溶剂体积明显减少(相对于所述水溶液法)。
(2)因为溶解度增加，所述方法的温度也相对低于水溶液法，由此避免脂肪酸酯的水解不稳定性。
(3)当温度回降至室温时，脂质的甲苯/甲醇溶液保持均质，使得可以室温过滤以去除固体外来物质。
(4)MTBE沉淀使得可以快速简便地分离脂质混合物固体。而所述水溶液法，要使用耗时的冷冻干燥过程分离物质。
(5)MTBE沉淀还使得可以去除进入过滤的废水流中的可溶于MTBE的任何杂质。当直接浓缩溶液或冷冻干燥至固体时，不能实现去除杂质的潜力。
(6)本发明方法提供均匀固体。
脂质悬浮物的制备步骤(1)：
在第一步中，脂质混合物与非水溶剂接触，因此所述脂质混合物基本上溶解于非水溶剂中。或者，可以使单独的脂质依次与所述非水溶剂接触，所述脂质次序为：DPPC、DPPA和MPEG5000-DPPE；DPPC、MPEG5000-DPPE和DPPA；MPEG5000-DPPE、DPPA和DPPC；或MPEG5000-DPPE、DPPC和DPPA。不首先加入脂质溶解最少以及脂质含量最少的DPPA。在加入DPPA前或与其同时加入一种其它脂质有助于DPPA的溶解。在另一替代方法中，各种脂质可以以其固体形式组合，该固体组合物与非水溶剂接触。
当脂质混合物和非水溶剂的混合物变透明时，一般表示基本溶解。如前所述，磷脂一般不是水溶性的。因此，磷脂混合物直接加入水环境中引起所述脂质混合物聚集形成非常难以分散的团块。本发明通过将脂质混合物在加入水溶液前溶解于非水溶剂中，从而克服该制约。这使得人们可以将脂质混合物均匀地分散到液体中。然后该液体分散物可以加入到所需要的水环境中。
非水的是指一种溶剂或溶剂的混合物，其中存在的水量足够低以便不影响所述脂质混合物的溶解。所需要的非水溶剂的量取决于脂质混合物的溶解度，并且还取决于各个组分的最终需要浓度。作为一个普通技术人员应该认识到，存在于非水溶剂中的可允许的水的水平随脂质混合物中的各种脂质的水溶解度而改变。各种磷脂的水溶解度越高，可以存在于步骤(1)中的水越多。最好是使用丙二醇作非水溶剂。然而，可以使用其它多羟基化合物家族成员，例如乙二醇和聚乙二醇300。
机械混合脂质混合物和非水溶剂可能是达到完全溶解所必需的。本领域普通技术人员将认识到，可用各种混合方法。最好使用高剪切均化器。
本领域技术人员应该认识到，升高溶剂的温度有助于脂质混合物的溶解。在可实施步骤(1)的温度范围可以从室温至选定溶剂的沸点温度。所述温度优选为约30-70℃，更优选为约45-60℃，甚至更优选为约50、51、52、53、54或55℃。当使用乙二醇或聚乙二醇300时，所述温度优选为约50℃-约60℃，而更优选为约55℃。保持所述溶液于较高温度将降低溶液粘度并便于配制。
溶解所述脂质混合物的优选方法如下：(a)将丙二醇加至合适称量容器中。(b)在热浴中加热丙二醇至约40-80℃。(C)称量脂质混合物装入分开的容器。(d)当丙二醇达到所需要的温度范围时，将该溶液转移入装有所述脂质混合物的容器中。(e)把该容器放回热浴中，直到所述溶液变为透明。(f)机械混合所述脂质混合物/丙二醇溶液以进一步保证完全溶解以及均匀分散所述脂质混合物。
当然，脂质混合物与非水溶剂的比率受限于所述脂质混合物的溶解度。该比率也将受到最终制剂中的脂质混合物的需要量的影响。优选的所述比率为从每mL溶剂约1mg脂质混合物(mg/mL)至约100mg/mL。更优选的是，所述脂质混合物以约5、6、7、8、9、10、11、12、13、14或15mg/mL存在。甚至更优选的是，所述脂质混合物以约10mg/mL存在。步骤(2)：
第二步包括使步骤(1)的溶液与水溶液接触形成脂质悬浮物。所述水溶液可以是水、盐水、盐水/甘油混合物或盐水/甘油/非水溶剂混合物。按如上定义，非水溶剂最好是丙二醇。作为本文所用的悬浮物是指其中不溶性颗粒分散于液体介质的分散物。
在所述脂质混合物达到完全溶解(步骤(1))后，可将所得的溶液加至水溶液中。该水溶液可以含有一种或多种选自氯化钠、甘油和非水溶剂的组分。该水溶液优选含有甘油和氯化钠。最好是，在加入步骤1的溶液前，在所述水溶液中存在足够量的丙二醇，以便达到所需要的丙二醇终浓度。
不希望所需组分的加入次序会严重影响所生成的脂质悬浮物。然而，所述脂质混合物液优选加至已经含有上述另外组分的水中。然后可以加入所需要的另外组分。更优选的是，所述脂质混合物液加至水和氯化钠的溶液(即盐水)中。还优选的是，所述脂质混合物液加至水、氯化钠和甘油的溶液中。甚至更优选的是，所述脂质混合物液加至水、氯化钠、甘油和丙二醇的溶液中。
优选的是，每mL制剂存在6.8mg氯化钠。优选每mL制剂存在0.1mL甘油。优选终浓度为每mL制剂0.1mL丙二醇。所述制剂的最终pH优选为约5.5-7.0。所述脂质混合物液最好是以每mL制剂0.75-1.0mg的量存在。
水溶液的温度范围可以是从室温到70℃。该温度优选为约45-60℃，甚至更优选50、51、52、53、54或55℃。为了达到完全溶解，需要振荡所述混合物，最好是搅拌。此外，可能需要根据所需要的最终制剂调节所述溶液的pH。可以加入酸(例如盐酸)或碱(例如氢氧化钠)以进行该调节。
所述脂质悬浮物将含有不同大小的液体颗粒。本发明的益处之一是能够恒定地获得几乎均匀大小的小颗粒。因此，最好是获得的大部分颗粒直径小于100nm，更优选小于50nm。
溶解所述脂质混合物的优选的方法如下：(a)将注射用水(WFI)加入混合容器。(b)开始混合并保证温度为50-55℃。(c)将氯化钠加至混合容器。在进行下一步前，等待直到所述固体完全溶解。(d)将甘油加至所述混合容器中。使其有足够时间以完全混合。(e)加入非所述脂质混合物/丙二醇溶液中的余下丙二醇。给予足够时间以充分混合。(f)降低混合率以减少混合容器中的湍流。(g)将所述脂质混合物/丙二醇溶液加至混合容器中。(h)再调节混合至原初速率。(i)必要时，加入另外的WFI。(i)连续混合约25分钟并保证完全混匀。(k)检验并调节该溶液至目标pH。步骤(3)：
第三步包括加热得自步骤(2)的脂质悬浮物至温度约等于或高于存在于该溶液中的脂质的凝胶至液晶的最高相变温度。
该步骤的目的之一是提供可过滤的悬浮物。假如在正常的过程中流速没有明显的下降而在该过滤系统中压力下降无明显的增加时，则认为溶液/悬浮物是可过滤的。
实验数据显示，所述制剂中的脂质应该超过其凝胶到液晶的相变，以便简化无菌过滤。当所述脂质低于所述相变温度时，所述悬浮物颗粒是刚性的。然而，当它们高于其相应的凝胶-液晶相变温度时，它们是更疏松结构的构型，因此更容易过滤。
DPPC和DPPA分别显示相变温度为41℃和67℃。MPEG5000-DPPE溶于水，因此它不表现出为大多数水合脂质悬浮物的特征的凝胶-液晶相变。因为优选的制剂中的脂质均显示不同的凝胶到液体的相变，所以最好使用最高相变温度67℃过滤所述溶液。通过维持温度于67℃或高于67℃，使得所有脂质高于其相应的相变，从而保证疏松的构型而通过所述过滤器。
通过于所述混合容器外套上热交换线圈可以实现加热。得自可控来源(例如热水浴或热水器)的热水/蒸气就会传递足够的热以维持所述混合液于设定的温度。也可以使用本领域技术人员已知的其它热源。步骤(4)：
通过除菌过滤器过滤所述脂质悬浮物从而进行第四步。该步骤之后的目的是提供基本上无菌的悬浮物。当过滤物含至少一个形成菌落的微生物的概率小于10-6时，则认为该过滤物基本上无菌。
最好用除菌过滤柱进行过滤。此外，可能需要强制溶液通过所述过滤器的手段(例如泵送或加压)。由于进行过滤的溶液需要保持在存在于溶液中的脂质的凝胶到液晶最高相变温度或高于该温度下，所以过滤应该在大致相同的温度下进行。为此，最好将过滤器(例如除菌过滤柱)密封在护套式过滤器外壳中，该外壳不断加热(例如通过来自温控水浴的热水流)，以保证所述悬浮物高于脂质相变温度。除菌过滤器的温度优选为50-100℃，更优选为60-90℃，甚至更优选70、71、72、73、74、75、76、77、78、79或80℃。
可以使用一个或多个除菌滤膜过滤所述悬浮物。需要的滤膜数目将取决于其除菌效果。最好使用两个滤膜。滤膜孔的大小受限于提供无菌悬浮物的需要。最好使用0.2μm亲水性滤膜。
优选配方的本体溶液通过两个0.2μm亲水性滤膜以约1L/分钟(1L/min)流速连续过滤长达3小时，即所述悬浮液通过过滤器总计180L。实验结果表明，无明显的滤膜阻塞。脂质分析表明，在所述过滤过程中没有可检测的脂质丢失(由于过滤介质累积引起的)。
优选配方的本体溶液于40℃-80℃混合，所述悬浮物在无菌过滤前冷却至室温。未观察到明显的滤膜阻塞，表明所述悬浮物颗粒大小分布完全低于0.2μm的滤膜孔大小。最好是在过滤过程中应用加热以便保证脂质混合物在无菌过滤物中的最大回收(即使脂质颗粒在过滤介质中的潜在保留最小化)。
过滤脂质悬浮物的优选方法如下：(a)保证所有装套的过滤器于70℃-80℃。(b)保证过滤装置中的阀关闭。(c)连接过滤入口软管至混合容器的出口。(d)打开阀使溶液通过所述滤器。(e)在收集过滤物前使3升溶液通过过滤器进行中洗。(f)连续过滤直至完成。步骤(5)：
将所述过滤液分配装入管制瓶从而完成第五步。最好是在可控无菌区进行该步骤。本领域一般技术人员应该认识到，选定的管制瓶和传递至管制瓶的悬浮物的量应该取决于所设想的脂质悬浮物的最终用途。通过各种方法可以实现分装，包括吸管、手动注射器式分配器(例如Filamatic注射器式分配器)或工业自动分配器(例如Cozzli或TL自动灌装机)。步骤(6)：
用全氟烃气交换得自步骤5的管制瓶的上部气体，从而进行第六步。交换的优选方法是把已分装的管制瓶载入冷冻干燥器室，用全氟烃气替换管制瓶上部气体。优选的气体是全氟丙烷(PFP)。可以使用本领域技术人员已知的上部气体交换的其它方法。
在完成所述管制瓶上部气体交换循环后，密封管制瓶。当所述冷冻干燥器压力下降回到大气压时，用PFP充入该室。固定管制瓶塞以封闭该管制瓶。步骤(7)：
第七步包括在步骤6后最后灭菌管制瓶。一种终末灭菌的方法是使用高压灭菌器。此外，所述密封管制瓶可以最后在蒸汽灭菌器中灭菌，以进一步提高所述产品的无菌保证。在灭菌过程中必须小心注意，因为可观察到高压灭菌引起的一定程度的脂质降解。最好是所述管制瓶于126-130℃灭菌1-10分钟。
本发明的其它特征在以下示例性实施方案的说明过程中将变得显而易见，给出所述实施方案是为了说明本发明而不是用来对其进行限制。
实施例
表1：脂质混合物的目标组成
    脂质名称     通用名 Wt％ 摩尔％
    DPPA  1,2-二棕榈酰基-sn-甘油基-3-磷脂酸一钠盐     6.0     10
    DPPC  1,2-二棕榈酰基-sn-甘油基-3-磷脂酰胆碱     53.5     80
 MPEG5000-DPPE  N-(甲氧基聚乙二醇5000氨基甲酰基)-1,2-二棕榈酰基-sn-甘油基-3-磷脂酰乙醇胺一钠盐     40.5     8
脂质混合物的生产方法
Figure 9980210200221
将甲苯(3.3L)、甲醇(1.2L)、DPPA(59.6g)、DPPC(535g)和MPEG5000 DPPE(405g)装入一个烧瓶中。用0.9L甲醇冲洗固体接触表面后，将该淤浆加热至45-55℃直到完全溶解。
过滤该溶液，然后于35-45℃真空浓缩成为稠密凝胶。加入甲基叔丁基醚(MTBE,5.4L)，将该混合物于15-30℃淤浆化。经离心或真空过滤收集白色固体，并用MTBE(0.9L)洗涤。然后将该固体放入真空炉中，并于40-50℃干燥至恒重。所干燥的脂质混合物转移至瓶中并保藏于-15-25℃。
在本发明脂质混合物生产方法的另一实施方案中，也可以使用以下方法。
脂质混合物的替代生产方法
Figure 9980210200231
根据分析证明“使用(Use As)”值的纯度调节磷脂量。该实验的批量大小(合并的磷脂重量)是2kg。
向旋转式蒸发瓶依次装入甲苯(3,300mL)、甲醇(1,200mL)、DPPA(122.9g，校正的“使用”纯度为97.0％)、DPPC(总量1,098.5g；500.8g取自98.4％“使用”纯度的一批，597.7g取自96.7％“使用”纯度的一批)和MPEG5000 DPPE(815.7g；校正的“使用”纯度为99.3％)。用甲醇(900mL)把残余的固体冲洗入所述烧瓶后，烧瓶放置于旋转蒸发器上(非真空)，将淤浆加热至45-55℃(外部)。完全溶解后，使所述外部温度降至35-45℃，采用真空，使溶液浓缩成白色半固体。从蒸发器取出烧瓶，用刮勺粉碎固体。烧瓶再用于蒸发器，继续浓缩。达到终点(最终真空压力为220mbar；白色颗粒型坚固固体)后，经旋转式蒸发器的加入管加入MTBE(5,400mL)，终止真空，所述混合物于15-30℃淤浆化15-45分钟。经离心或真空过滤分离固体，用MTBE(3,800mL)冲洗，在真空炉(40-50℃)中干燥至恒重。在转移至带聚丙烯盖的聚乙烯瓶中以前，使固体过筛(0.079英寸目)去除固体块，提供为白色固体的脂质混合物(SG896)1,966.7g(98％)。
优选的脂质悬浮物含有：
1,2-二棕榈酰基-sn-甘油基-3-磷脂酸一钠盐(DPPA)；
1,2-二棕榈酰基-sn-甘油基-3-磷脂酰胆碱(DPPC)；
V-(甲氧基聚乙二醇5000氨基甲酰基)-1,2-二棕榈酰基-sn-甘
油基-3-磷脂酰乙醇胺一钠盐(MPEG5000-DPPE)；
聚乙二醇，USP；
甘油，USP；
氯化钠，USP；和，
注射用水，USP。
表2：优选的对照剂配方
    组分     A*     B*
氯化钠，USP     6.8mg/mL     6.8mg/mL
甘油，USP     0.1mL/mL     0.1mL/mL
聚乙二醇，USP     0.1mL/mL     0.1mL/mL
脂质混合物**     1mg/mL     0.75mg/mL
全氟丙烷     ＞65％     ＞65％
pH     6.0-7.0     6.0-7.0
*配方A的脂质混合物浓度为1mg/mL；配方B的脂质混合物浓度为0.75mg/mL。**该脂质混合物包含：DPPC 53.5wt.％，DPPA 6.0wt.％和MPEG5000-DPPE 40.5wt.％。
表3：优选的容器和封闭
    组分     类型
管制瓶 Wheaton 2802,B33BA,2cc,13mm,I型，火石玻璃管形瓶
    瓶塞 West V50 4416/50,13mm，灰色丁基lyo的硅化塞
    密封 West 3766，白色13mm，轻按脱落式铝密封
成品的装量体积可以为1.0-2.0mL/管制瓶。
在优选配方的制备中，当所述脂质混合物与含注射用水、氯化钠、甘油和丙二醇的水基质溶液直接水合时，与过滤前的本体溶液相比，所述过滤物的脂质含量较少。脂质的丢失量变化范围12％-48％。这些结果证实，所述无菌过滤过程是不能有效控制的，因此成品的脂质含量是高度变异的。
相反，用目前描述的方法，所述脂质的分析结果表明脂质在所述过滤过程中全部回收。分析结果在理论值附近的变化是在正常的分析方法变异范围内。由在丙二醇中的第一种溶解脂质混合物制备的悬浮物的数目、体积和反射密度的颗粒大小分布表明，在55℃以及70℃的过滤前本体溶液中，大多数颗粒小于50nm。颗粒分布型过滤后没有变化。
应用部分
现在要求保护的方法用于制备超声造影剂。这类造影剂应该可用于各种成像应用，包括在超声心动图和放射性超声显像中增强对比度。
显然，根据上述内容对本发明进行各种改进和改变是可能的。因此，理所当然的是，在后附的权利要求范围内，可以如本文所具体描述的其它内容实施本发明。

Claims (44)

1．一种制备磷脂悬浮物的方法，包括：
(1)使磷脂混合物与非水溶剂接触，由此使所述磷脂混合物基本上溶解于所述非水溶剂中，以及
(2)使得自步骤(1)的溶液与水溶液接触形成脂质悬浮物。
2．按照权利要求1的方法，其中所述非水溶剂选自丙二醇、乙二醇和聚乙二醇300。
3．按照权利要求2的方法，其中所述非水溶剂是丙二醇。
4．按照权利要求2的方法，其中所述脂质混合物包括：
(a)1,2-二棕榈酰基-sn-甘油基-3-磷脂酰胆碱；
(b)1,2-二棕榈酰基-sn-甘油基-3-磷脂酸一钠盐；和
(c)N-(甲氧基聚乙二醇5000氨基甲酰基)-1,2-二棕榈酰基-sn-甘油基-磷脂酰乙醇胺一钠盐。
5．按照权利要求2的方法，其中所述非水溶剂在与所述脂质混合物接触前加热至温度约30-70℃。
6．按照权利要求5的方法，其中所述非水溶剂在与所述脂质混合物接触前加热至温度约50-55℃。
7．按照权利要求2的方法，其中脂质混合物与非水溶剂的比率为每mL非水溶剂约含5mg脂质混合物至约15mg/mL。
8．按照权利要求7的方法，其中脂质混合物与非水溶剂的比率约为10mg/mL。
9．按照权利要求2的方法，其中在步骤(2)中，所述水溶液选自水、盐水、盐水/甘油混合物和盐水/甘油/非水溶剂混合物。
10．按照权利要求9的方法，其中所述水溶液是盐水和甘油的混合物。
11．按照权利要求9的方法，其中所述水溶液是盐水、甘油和丙二醇的混合物。
12．按照权利要求11的方法，其中存在氯化钠6.8mg/mL，存在甘油0.1mL/mL，存在丙二醇0.1mL/mL以及存在所述脂质混合物约0.75-1.0mg/mL。
13．按照权利要求12的方法，其中存在脂质混合物0.75mg/mL。
14．按照权利要求12的方法，其中存在脂质混合物1.0mg/mL。
15．按照权利要求2的方法，其中在步骤(2)中，所述水溶液在与得自步骤(1)的溶液接触以前加热至温度约45-60℃。
16．按照权利要求15的方法，其中所述水溶液在与得自步骤(1)的溶液接触前加热至温度约50-55℃。
17．按照权利要求1的方法，其中所述方法还包括：
(3)加热得自步骤(2)的脂质悬浮物至温度约等于或高于存在于所述悬浮物中的脂质的凝胶到液晶的最高相变温度。
18．按照权利要求17的方法，其中在步骤(3)中，所述脂质悬浮物加热至温度至少约67℃。
19．按照权利要求17的方法，其中所述方法还包括：
(4)所述脂质悬浮物通过无菌过滤器过滤。
20．按照权利要求19的方法，其中在步骤(4)中，用两根无菌过滤柱进行过滤。
21．按照权利要求20的方法，其中在步骤(4)中，所述除菌过滤柱的温度约70-80℃。
22．按照权利要求21的方法，其中在步骤(4)中，使用0.2μm的亲水性滤膜。
23．按照权利要求19的方法，其中所述方法还包括：
(5)将得自步骤(4)的过滤的溶液分装入管制瓶中。
24．按照权利要求23的方法，其中所述方法还包括：
(6)用全氟烃气替换得自步骤(5)的管制瓶上部的气体。
25．按照权利要求24的方法，其中所述全氟烃气为全氟两烷。
26．按照权利要求25的方法，其中用冷冻干燥室进行上部气体的交换。
27．按照权利要求24的方法，其中所述方法还包括：
(7)消毒得自步骤(6)的管制瓶。
28．按照权利要求27的方法，其中在步骤(7)中，所述管制瓶于约126-130℃消毒1-10分钟。
29．一种制备脂质混合物的方法，包括：
(a)使至少两种脂质与第一种非水溶剂接触；
(b)浓缩该溶液至稠密凝胶；
(c)使稠密凝胶与第二种非水溶剂接触；以及，
(d)收集所得的固体。
30．按照权利要求29的方法，其中在步骤(a)中，所述脂质是：
(ⅰ)1,2-二棕榈酰基-sn-甘油基-3-磷脂酰胆碱；
(ⅱ)1,2-二棕榈酰基-sn-甘油基-3-磷脂酸一钠盐；和
(ⅲ)N-(甲氧基聚乙二醇5000氨基甲酰基)-1,2-二棕榈酰基-sn-甘油基-3-磷脂酰乙醇胺一钠盐。
31．按照权利要求30的方法，其中在步骤(a)中，所述第一种非水溶剂是甲醇和甲苯的混合物。
32．按照权利要求30的方法，其中在步骤(c)中，所述第二种非水溶剂是甲基叔丁基醚。
33．按照权利要求30的方法，其中在步骤(a)中，将所述溶液加热至足以使所述脂质完全溶解到所述溶剂中的温度。
34．按照权利要求33的方法，其中在步骤(a)中，将所述溶液加热至约25-75℃。
35．按照权利要求30的方法，其中在步骤(d)中，所收集的固体用甲基叔丁基醚洗涤并在真空干燥。
36．一种磷脂悬浮物，包括：
(a)悬浮物的脂质混合物量约0.75-1.0mg/mL；
(b)悬浮物的氯化钠量约6.8mg/mL；
(c)悬浮物的甘油量约0.1mL/mL；
(d)悬浮物的丙二醇量约0.1mL/mL；以及
(e)水；
其中所述悬浮物通过所述方法制备，该方法包括：
(1)使脂质混合物与非水溶剂接触，由此使所述脂质混合物基本上溶解于所述非水溶剂中。
(2)使得自步骤(1)的溶液与水溶液接触形成脂质悬浮物；
(3)将得自步骤(2)的脂质悬浮物加热至温度约等于或高于存在于所述悬浮物中的脂质的凝胶到液晶的最高相变温度。
(4)通过除菌过滤器过滤所述脂质悬浮物。
37．一种按照权利要求36的磷脂悬浮物，其中所述脂质混合物包括：
(a)1,2-二棕榈酰基-sn-甘油基-3-磷脂酰胆碱；
(b)1,2-二棕榈酰基-sn-甘油基-3-磷脂酸一钠盐；和
(c)N-(甲氧基聚乙二醇5000氨基甲酰基)-1,2-二棕榈酰基-sn-甘油基-3-磷脂酰乙醇胺一钠盐。
38．一种按照权利要求37的磷脂悬浮物，其中所述非水溶剂在与所述脂质混合物接触前加热至温度约50-55℃。
39．一种按照权利要求37的磷脂悬浮物，其中脂质混合物与非水溶剂的比率为约10mg/mL。
40．一种按照权利要求37的磷脂悬浮物，其中所述水溶液是盐水、甘油和丙二醇的混合物。
41．一种按照权利要求40的磷脂悬浮物，其中存在脂质混合物0.75mg/mL。
42．一种按照权利要求37的磷脂悬浮物，其中所述水溶液在与得自步骤(1)的溶液接触前加热至温度约50-55℃。
43．一种按照权利要求37的磷脂悬浮物，其中在步骤(3)中，将所述脂质悬浮物加热至温度至少约67℃。
44．一种按照权利要求43的磷脂悬浮物，其中在步骤(4)中，使用两个0.2μm亲水性滤膜。
CNB998021024A 1998-01-14 1999-01-14 脂质混合物以及含该脂质混合物的磷脂悬浮物的制备 Expired - Lifetime CN1191822C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7133298P 1998-01-14 1998-01-14
US60/071,332 1998-01-14

Publications (2)

Publication Number Publication Date
CN1288373A true CN1288373A (zh) 2001-03-21
CN1191822C CN1191822C (zh) 2005-03-09

Family

ID=22100659

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998021024A Expired - Lifetime CN1191822C (zh) 1998-01-14 1999-01-14 脂质混合物以及含该脂质混合物的磷脂悬浮物的制备

Country Status (31)

Country Link
US (8) US20010003580A1 (zh)
EP (2) EP1419789B1 (zh)
JP (2) JP5160702B2 (zh)
KR (1) KR100711663B1 (zh)
CN (1) CN1191822C (zh)
AR (1) AR016444A1 (zh)
AT (1) ATE447976T1 (zh)
AU (1) AU746067C (zh)
BR (1) BR9907066A (zh)
CA (1) CA2317921C (zh)
DE (1) DE69941634D1 (zh)
DK (1) DK1419789T3 (zh)
EA (1) EA002978B1 (zh)
EE (1) EE04900B1 (zh)
ES (1) ES2336669T3 (zh)
HK (1) HK1064301A1 (zh)
HR (1) HRP990012A2 (zh)
HU (1) HUP0100206A3 (zh)
IL (2) IL137018A0 (zh)
MY (1) MY137255A (zh)
NO (1) NO321866B1 (zh)
NZ (1) NZ505082A (zh)
PH (1) PH12012000094A1 (zh)
PL (1) PL193672B1 (zh)
PT (1) PT1419789E (zh)
SI (1) SI1419789T1 (zh)
SK (1) SK285333B6 (zh)
TW (1) TWI242448B (zh)
UA (1) UA75023C2 (zh)
WO (1) WO1999036104A2 (zh)
ZA (1) ZA99247B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1321697C (zh) * 2003-12-23 2007-06-20 中国人民解放军军事医学科学院毒物药物研究所 一种以磷脂类成分为成膜材料的超声造影剂组合物及其制备方法

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006200015B8 (en) * 1998-01-14 2008-02-21 Dupont Pharmaceuticals Company Preparation of a lipid blend and a phospholipid suspension containing a lipid blend, and contrast agents based on these
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
US6975924B2 (en) * 1999-12-03 2005-12-13 Baxter International Inc. Method and apparatus for controlling the strategy of compounding pharmaceutical admixtures
US20030049158A1 (en) * 2001-04-03 2003-03-13 Hui Poh K. Stablization and terminal sterilization of phospholipid formulations
SI1476201T1 (sl) 2002-02-19 2009-06-30 Resolution Chemicals Ltd Sterilizacija steroidov, osnovana na topilu
US9364569B2 (en) * 2003-02-04 2016-06-14 Bracco Suisse S.A. Ultrasound contrast agents and process for the preparation thereof
CA2547024C (en) 2003-12-22 2013-12-17 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
US7854943B2 (en) 2004-06-24 2010-12-21 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US7858115B2 (en) * 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US7618651B2 (en) 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
WO2006018433A1 (en) 2004-08-18 2006-02-23 Bracco Research Sa Gas-filled microvesicles composition for contrast imaging
US8017159B2 (en) * 2005-11-16 2011-09-13 Idexx Laboratories, Inc. Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same
KR20110110086A (ko) * 2008-12-24 2011-10-06 가부시키가이샤 바이오메드코어 리포솜의 제조방법 및 콜레스테롤의 용해방법
JP5771366B2 (ja) * 2009-09-02 2015-08-26 株式会社バイオメッドコア リポソーム製造装置及び方法
JP2012086166A (ja) * 2010-10-20 2012-05-10 Biomedcore Inc リポソーム製造装置
WO2014138035A1 (en) 2013-03-04 2014-09-12 Echogen Power Systems, L.L.C. Heat engine systems with high net power supercritical carbon dioxide circuits
TWI552761B (zh) * 2013-05-03 2016-10-11 博信生物科技股份有限公司 一種脂質微／奈米氣泡、及其最佳化之製備方法及製備裝置
GB201411423D0 (en) 2014-06-26 2014-08-13 Ge Healthcare As Lipid sterilisation method
KR20230015509A (ko) * 2014-10-30 2023-01-31 랜티우스 메디컬 이메징, 인크. 지질 캡슐화된 기체 마이크로스피어 조성물 및 관련된 방법
US10570777B2 (en) 2014-11-03 2020-02-25 Echogen Power Systems, Llc Active thrust management of a turbopump within a supercritical working fluid circuit in a heat engine system
CN107206111B (zh) 2014-12-31 2021-04-27 蓝瑟斯医学影像公司 脂质封装的气体微球组合物及相关方法
CN109641068B (zh) * 2016-05-04 2022-09-30 蓝瑟斯医学影像公司 用于制备超声波造影剂的方法及装置
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
WO2019036253A1 (en) * 2017-08-15 2019-02-21 The Board Of Trustees Of The Leland Stanford Junior University POLYMERIC PERFLUOROCARBON NANOEMULSIONS FOR ULTRASOUND MEDICATION DELIVERY
EP3905995A4 (en) 2019-01-04 2022-08-31 California Institute of Technology PROCEDURE FOR EYE LENS REMOVAL USING CAVITATION MICROBUBBLE
RU2745290C2 (ru) * 2019-04-12 2021-03-23 Ирина Николаевна Кузнецова Эмульсия перфторуглеродных соединений медико-биологического назначения и способ её получения
US11435120B2 (en) 2020-05-05 2022-09-06 Echogen Power Systems (Delaware), Inc. Split expansion heat pump cycle
NL2027237B1 (en) 2020-12-27 2022-07-21 Solstice Pharmaceuticals B V Process for controlled manufacturing of mono-disperse microbubbles

Family Cites Families (396)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3015128A (en) 1960-08-18 1962-01-02 Southwest Res Inst Encapsulating apparatus
NL302030A (zh) 1962-12-21 1900-01-01
US3291843A (en) 1963-10-08 1966-12-13 Du Pont Fluorinated vinyl ethers and their preparation
BE661981A (zh) 1964-04-03
US3594326A (en) 1964-12-03 1971-07-20 Ncr Co Method of making microscopic capsules
US3968203A (en) 1965-10-01 1976-07-06 Jerome G. Spitzer Aerosol astringent composition
US3488714A (en) 1966-09-19 1970-01-06 Dow Chemical Co Formed laminate structure and method of preparation
US3615972A (en) 1967-04-28 1971-10-26 Dow Chemical Co Expansible thermoplastic polymer particles containing volatile fluid foaming agent and method of foaming the same
US3532500A (en) 1967-07-25 1970-10-06 Eastman Kodak Co Light sensitive vesicular composition comprising an azido-s-triazine compound
US3557294A (en) 1967-10-12 1971-01-19 Allied Chem Fluorinated ethers as inhalation convulsants
US3479811A (en) 1967-11-29 1969-11-25 Dow Chemical Co Yarn and method of making the same
US3732172A (en) 1968-02-28 1973-05-08 Ncr Co Process for making minute capsules and prefabricated system useful therein
US3650831A (en) 1969-03-10 1972-03-21 Armour Dial Inc Method of cleaning surfaces
US4027007A (en) 1970-12-09 1977-05-31 Colgate-Palmolive Company Antiperspirants formulated with borax
US3873564A (en) 1971-03-03 1975-03-25 Synvar Ass 2-Imidazolinyl-3-oxide-1-oxypropionic acid
US4108806A (en) 1971-12-06 1978-08-22 The Dow Chemical Company Thermoplastic expandable microsphere process and product
US4179546A (en) 1972-08-28 1979-12-18 The Dow Chemical Company Method for expanding microspheres and expandable composition
US3960583A (en) 1974-05-02 1976-06-01 Philadelphia Quartz Company Method of preparing modified hollow, largely spherical particles by spray drying
CH588887A5 (zh) 1974-07-19 1977-06-15 Battelle Memorial Institute
US3945956A (en) * 1975-06-23 1976-03-23 The Dow Chemical Company Polymerization of styrene acrylonitrile expandable microspheres
US4138383A (en) 1975-11-24 1979-02-06 California Institute Of Technology Preparation of small bio-compatible microspheres
US4004384A (en) 1976-02-06 1977-01-25 Curoco Stairway unit
GB1523965A (en) 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
US4162282A (en) 1976-04-22 1979-07-24 Coulter Electronics, Inc. Method for producing uniform particles
GB1599881A (en) 1977-02-02 1981-10-07 Millington A R Preparation for diagnostic radiology
CH624011A5 (zh) 1977-08-05 1981-07-15 Battelle Memorial Institute
CH621479A5 (zh) 1977-08-05 1981-02-13 Battelle Memorial Institute
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4192859A (en) 1978-09-29 1980-03-11 E. R. Squibb & Sons, Inc. Contrast media containing liposomes as carriers
US4310506A (en) 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
US4276885A (en) 1979-05-04 1981-07-07 Rasor Associates, Inc Ultrasonic image enhancement
US4265251A (en) 1979-06-28 1981-05-05 Rasor Associates, Inc. Method of determining pressure within liquid containing vessel
US4303736A (en) 1979-07-20 1981-12-01 Leonard Torobin Hollow plastic microspheres
US4310505A (en) 1979-11-08 1982-01-12 California Institute Of Technology Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4342826A (en) 1980-02-04 1982-08-03 Collaborative Research, Inc. Immunoassay products and methods
US4421562A (en) 1980-04-13 1983-12-20 Pq Corporation Manufacturing process for hollow microspheres
US4344929A (en) 1980-04-25 1982-08-17 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4315514A (en) 1980-05-08 1982-02-16 William Drewes Method and apparatus for selective cell destruction
US4331654A (en) 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
US4442843A (en) 1980-11-17 1984-04-17 Schering, Ag Microbubble precursors and methods for their production and use
WO1982001642A1 (en) 1980-11-17 1982-05-27 Med Inc Ultra Microbubble precursors and methods for their production and use
US4681119A (en) 1980-11-17 1987-07-21 Schering Aktiengesellschaft Method of production and use of microbubble precursors
US4657756A (en) 1980-11-17 1987-04-14 Schering Aktiengesellschaft Microbubble precursors and apparatus for their production and use
US4420442A (en) 1981-04-13 1983-12-13 Pq Corporation Manufacturing process for hollow microspheres
US4533254A (en) 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
EP0068961A3 (fr) 1981-06-26 1983-02-02 Thomson-Csf Dispositif d'échauffement localisé de tissus biologiques
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4569836A (en) 1981-08-27 1986-02-11 Gordon Robert T Cancer treatment by intracellular hyperthermia
IL63734A (en) * 1981-09-04 1985-07-31 Yeda Res & Dev Lipid fraction,its preparation and pharmaceutical compositions containing same
EP0088773B1 (en) 1981-09-23 1987-09-09 M.B. Fillers Pty. Ltd. Hollow, bilayered silicate microspheres
DE3141641A1 (de) 1981-10-16 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Ultraschall-kontrastmittel und dessen herstellung
BR8107560A (pt) 1981-11-19 1983-07-05 Luiz Romariz Duarte Estimulacao ultra-sonica da consolidacao de fraturas osseas
US4748216A (en) * 1982-01-25 1988-05-31 Hercules Incorporated Purified cycloolefin polymerization composition
US4522803A (en) * 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4540629A (en) 1982-04-08 1985-09-10 Pq Corporation Hollow microspheres with organosilicon-silicate walls
JPS58201711A (ja) * 1982-05-19 1983-11-24 Eisai Co Ltd ユビデカレノン含有リポソ−ム被覆体
DE3225848A1 (de) 1982-07-07 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen Kortikoidhaltige zubereitung zur topischen applikation
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
DE3374522D1 (zh) * 1982-10-26 1987-12-23 University Of Aberdeen
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4731239A (en) 1983-01-10 1988-03-15 Gordon Robert T Method for enhancing NMR imaging; and diagnostic use
GB8301506D0 (en) 1983-01-20 1983-02-23 Electricity Council Fluorinated ethers
US4718433A (en) 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US4572203A (en) 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4775522A (en) 1983-03-04 1988-10-04 Children's Hospital Research Foundation, A Division Of Children's Hospital Medical Center NMR compositions for indirectly detecting a dissolved gas in an animal
US4981692A (en) 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US5141738A (en) 1983-04-15 1992-08-25 Schering Aktiengesellschaft Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
US4485193A (en) 1983-05-10 1984-11-27 The Dow Chemical Company Expandable synthetic resinous thermoplastic particles, method for the preparation thereof and the application therefor
US4515736A (en) * 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4900540A (en) 1983-06-20 1990-02-13 Trustees Of The University Of Massachusetts Lipisomes containing gas for ultrasound detection
JPS607932A (ja) * 1983-06-29 1985-01-16 Dai Ichi Seiyaku Co Ltd リポソーム懸濁液およびその製法
JPS6019033A (ja) 1983-07-12 1985-01-31 Matsumoto Yushi Seiyaku Kk 中空マイクロバル−ンおよびその製法
US4519024A (en) 1983-09-02 1985-05-21 At&T Bell Laboratories Two-terminal transistor rectifier circuit arrangement
US4615879A (en) 1983-11-14 1986-10-07 Vanderbilt University Particulate NMR contrast agents for gastrointestinal application
FR2563725B1 (fr) 1984-05-03 1988-07-15 Dory Jacques Appareil d'examen et de localisation de tumeurs par ultrasons muni d'un dispositif de traitement localise par hyperthermie
SE463651B (sv) 1983-12-21 1991-01-07 Nycomed As Diagnostikum och kontrastmedel
EP0158441B2 (en) * 1984-03-08 2001-04-04 Phares Pharmaceutical Research N.V. Liposome-forming composition
GB8407557D0 (en) 1984-03-23 1984-05-02 Hayward J A Polymeric lipsomes
CH668554A5 (de) * 1984-04-09 1989-01-13 Sandoz Ag Liposomen welche polypeptide mit interleukin-2-aktivitaet enthalten sowie verfahren zu ihrer herstellung.
US4728575A (en) 1984-04-27 1988-03-01 Vestar, Inc. Contrast agents for NMR imaging
US5008109A (en) 1984-05-25 1991-04-16 Vestar, Inc. Vesicle stabilization
CA1264668A (en) 1984-06-20 1990-01-23 Pieter R. Cullis Extrusion techniques for producing liposomes
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4620546A (en) 1984-06-30 1986-11-04 Kabushiki Kaisha Toshiba Ultrasound hyperthermia apparatus
SE8403905D0 (sv) 1984-07-30 1984-07-30 Draco Ab Liposomes and steroid esters
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4761288A (en) * 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
US4767610A (en) 1984-10-19 1988-08-30 The Regents Of The University Of California Method for detecting abnormal cell masses in animals
US4789501A (en) 1984-11-19 1988-12-06 The Curators Of The University Of Missouri Glass microspheres
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4753788A (en) * 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
US4830858A (en) 1985-02-11 1989-05-16 E. R. Squibb & Sons, Inc. Spray-drying method for preparing liposomes and products produced thereby
US4689986A (en) 1985-03-13 1987-09-01 The University Of Michigan Variable frequency gas-bubble-manipulating apparatus and method
US5186922A (en) 1985-03-15 1993-02-16 See/Shell Biotechnology, Inc. Use of biodegradable microspheres labeled with imaging energy constrast materials
US4680171A (en) * 1985-03-15 1987-07-14 William Shell Visualization of a bloodstream circulation with biodegradable microspheres
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
DE3686025T2 (de) 1985-05-22 1993-01-07 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
US4683092A (en) * 1985-07-03 1987-07-28 Damon Biotech, Inc. Capsule loading technique
DE3677112D1 (de) 1985-08-12 1991-02-28 Battelle Memorial Institute Poroese filtrierungsglaskugeln und methode zu deren herstellung.
DE3529195A1 (de) * 1985-08-14 1987-02-26 Max Planck Gesellschaft Kontrastmittel fuer ultraschalluntersuchungen und verfahren zu seiner herstellung
US4684479A (en) 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US4938947A (en) 1985-11-01 1990-07-03 Centre National De La Recherche Scientifique (Cnrs) Aerosol composition for in vivo imaging
US5080885A (en) 1986-01-14 1992-01-14 Alliance Pharmaceutical Corp. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US4987154A (en) 1986-01-14 1991-01-22 Alliance Pharmaceutical Corp. Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use
US4865836A (en) 1986-01-14 1989-09-12 Fluoromed Pharmaceutical, Inc. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US4927623A (en) 1986-01-14 1990-05-22 Alliance Pharmaceutical Corp. Dissolution of gas in a fluorocarbon liquid
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
US5514720A (en) 1986-07-09 1996-05-07 Hemagen/Pfc Stable emulsions of highly fluorinated organic compounds
US5536753A (en) 1986-01-24 1996-07-16 Children's Hospital Research Foundation, A Division Of Children's Hospital Medical Center And Hemagen/Pfc Stable perfluorocarbon and oil emulsions
US5684050A (en) 1986-01-24 1997-11-04 Hemagen/Pfc Stable emulsions of highly fluorinated organic compounds
ES2054658T3 (es) 1986-01-24 1994-08-16 Childrens Hosp Medical Center Metodo para la preparacion de una emulsion fisiologicamente aceptable.
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4834964A (en) 1986-03-07 1989-05-30 M.R.I., Inc. Use of charged nitroxides as NMR image enhancing agents for CSF
JPH0751496B2 (ja) 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
DE3614657A1 (de) 1986-04-30 1987-11-05 Dornier Medizintechnik Pharmaka enthaltende lipidvesikel, verfahren zu ihrer herstellung und einbringung in den koerper eines lebewesens und freisetzung der in den lipidvesikeln enthaltende pharmaka
JPS62286534A (ja) 1986-06-04 1987-12-12 Matsumoto Yushi Seiyaku Kk 熱膨張性マイクロカプセルの製造法
IL79559A0 (en) 1986-07-29 1986-10-31 Univ Ramot Contrast agents for nmr medical imaging
FR2602774B1 (fr) 1986-07-29 1990-10-19 Atta Nouvelles molecules amphiphiles polyhydroxylees et perfluoroalkylees ayant des proprietes tensioactives
US4728578A (en) 1986-08-13 1988-03-01 The Lubrizol Corporation Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers
US4776991A (en) 1986-08-29 1988-10-11 The United States Of America As Represented By The Secretary Of The Navy Scaled-up production of liposome-encapsulated hemoglobin
US4781871A (en) 1986-09-18 1988-11-01 Liposome Technology, Inc. High-concentration liposome processing method
US4769241A (en) 1986-09-23 1988-09-06 Alpha Therapeutic Corporation Apparatus and process for oxygenation of liquid state dissolved oxygen-carrying formulation
JPS6360943U (zh) 1986-10-09 1988-04-22
ZW11287A1 (en) 1986-11-04 1989-01-25 Aeci Ltd Process for the production of an explosive
DE3637926C1 (de) 1986-11-05 1987-11-26 Schering Ag Ultraschall-Manometrieverfahren in einer Fluessigkeit mittels Mikroblaeschen
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US4863717A (en) 1986-11-10 1989-09-05 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Methods for circumventing the problem of free radial reduction associated with the use of stable nitroxide free radicals as contrast agents for magnetic reasonance imaging
US4933121A (en) 1986-12-10 1990-06-12 Ciba Corning Diagnostics Corp. Process for forming liposomes
DK175531B1 (da) 1986-12-15 2004-11-22 Nexstar Pharmaceuticals Inc Leveringsvehikel med amphiphil-associeret aktiv bestanddel
US5174930A (en) * 1986-12-31 1992-12-29 Centre National De La Recherche Scientifique (Cnrs) Process for the preparation of dispersible colloidal systems of amphiphilic lipids in the form of oligolamellar liposomes of submicron dimensions
FR2608942B1 (fr) 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
FR2634375B3 (fr) * 1988-06-30 1991-07-05 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles de lipide amphiphiles sous forme de liposomes submicroniques
US5283255A (en) 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US5089181A (en) * 1987-02-24 1992-02-18 Vestar, Inc. Method of dehydrating vesicle preparations for long term storage
CA1321048C (en) 1987-03-05 1993-08-10 Robert W. J. Lencki Microspheres and method of producing same
US5219538A (en) 1987-03-13 1993-06-15 Micro-Pak, Inc. Gas and oxygen carrying lipid vesicles
US5000960A (en) 1987-03-13 1991-03-19 Micro-Pak, Inc. Protein coupling to lipid vesicles
US4722943A (en) * 1987-03-19 1988-02-02 Pierce & Stevens Corporation Composition and process for drying and expanding microspheres
US4895876A (en) 1987-03-20 1990-01-23 Air Products And Chemicals, Inc. Concentrated stable fluorochemical aqueous emulsions containing triglycerides
US4866096A (en) 1987-03-20 1989-09-12 Air Products And Chemicals, Inc. Stable fluorochemical aqueous emulsions
JPS63277618A (ja) * 1987-03-31 1988-11-15 Noebia:Kk リポソ−ムの製造方法
CH672733A5 (zh) 1987-05-22 1989-12-29 Bracco Ind Chimica Spa
US5053214A (en) * 1987-06-19 1991-10-01 Manville Corporation Process for producing zirconium based granules
DE3851442T2 (de) 1987-06-23 1995-01-19 Nycomed Innovation Ab Verbesserungen bei der Bilderzeugung mittels magnetischer Resonanz.
US5354549A (en) 1987-07-24 1994-10-11 Nycomed Imaging As Iodinated esters
US4978483A (en) 1987-09-28 1990-12-18 Redding Bruce K Apparatus and method for making microcapsules
US5178875A (en) * 1991-01-14 1993-01-12 The Board Of Regents, The University Of Texas System Liposomal-polyene preliposomal powder and method for its preparation
US4839702A (en) 1987-11-20 1989-06-13 Bell Communications Research, Inc. Semiconductor device based on charge emission from a quantum well
US4873035A (en) * 1987-11-25 1989-10-10 Abbott Laboratories Preparation of sized populations of liposomes
DE3741201A1 (de) 1987-12-02 1989-06-15 Schering Ag Ultraschallarbeitsverfahren und mittel zu dessen durchfuehrung
IE61591B1 (en) 1987-12-29 1994-11-16 Molecular Biosystems Inc Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
US4844882A (en) 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
US5425366A (en) 1988-02-05 1995-06-20 Schering Aktiengesellschaft Ultrasonic contrast agents for color Doppler imaging
EP0586875A1 (de) 1988-02-05 1994-03-16 Schering Aktiengesellschaft Ultraschallkontrastmittel, Verfahren zu deren Herstellung und deren Verwendung als Diagnostika und Therapeutika
DE3803972A1 (de) 1988-02-05 1989-08-10 Schering Ag Ultraschallkontrastmittel
US4898734A (en) 1988-02-29 1990-02-06 Massachusetts Institute Of Technology Polymer composite for controlled release or membrane formation
DE3812816A1 (de) 1988-04-16 1989-11-02 Lawaczeck Ruediger Dipl Phys P Verfahren zur solubilisierung von liposomen und/oder biologischer membranen sowie deren verwendung
US5171755A (en) 1988-04-29 1992-12-15 Hemagen/Pfc Emulsions of highly fluorinated organic compounds
US4893624A (en) 1988-06-21 1990-01-16 Massachusetts Institute Of Technology Diffuse focus ultrasound hyperthermia system
DE3824354A1 (de) 1988-07-19 1990-01-25 Basf Ag, 67063 Ludwigshafen Verfahren zur herstellung von zellhaltigen kunststoffen nach dem polyisocyanat-polyadditionsverfahren mittels lagerstabiler, treibmittelhaltiger emulsionen und diese emulsionen
US4993415A (en) 1988-08-19 1991-02-19 Alliance Pharmaceutical Corp. Magnetic resonance imaging with perfluorocarbon hydrides
US4996041A (en) 1988-08-19 1991-02-26 Toshiyuki Arai Method for introducing oxygen-17 into tissue for imaging in a magnetic resonance imaging system
DE3828905A1 (de) 1988-08-23 1990-03-15 Schering Ag Mittel bestehend aus cavitate oder clathrate bildenden wirt/gast-komplexen als kontrastmittel
US5730954A (en) * 1988-08-23 1998-03-24 Schering Aktiengesellschaft Preparation comprising cavitate- or clathrate-forming host/guest complexes as contrast agent
US5045304A (en) 1988-08-31 1991-09-03 Wayne State University Contras agent having an imaging agent coupled to viable granulocytes for use in magnetic resonance imaging of abscess and a method of preparing and using same
US5410516A (en) 1988-09-01 1995-04-25 Schering Aktiengesellschaft Ultrasonic processes and circuits for performing them
DE3829999A1 (de) 1988-09-01 1990-03-15 Schering Ag Ultraschallverfahren und schaltungen zu deren durchfuehrung
US4957656A (en) * 1988-09-14 1990-09-18 Molecular Biosystems, Inc. Continuous sonication method for preparing protein encapsulated microbubbles
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
FR2637182B1 (fr) 1988-10-03 1992-11-06 Lvmh Rech Compositions a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un ecdysteroide, de preference l'ecdysterone, ou l'un de ses derives; et compositions cosmetiques, pharmaceutiques, notamment dermatologiques, de sericulture ou phytosanitaires l'incorporant
GB8824593D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Liposomes
JPH04501723A (ja) 1988-11-09 1992-03-26 アンガー，エヴァン，シー． リポソーム性放射線造影剤
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
LU87449A1 (fr) 1989-02-09 1990-09-19 Oreal Procede de fabrication de mousses utilisables dans les domaines cosmetique et pharmaceutique et mousses obtenues par ce procede
FR2645866B1 (fr) 1989-04-17 1991-07-05 Centre Nat Rech Scient Nouvelles lipopolyamines, leur preparation et leur emploi
US5114703A (en) 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
EP0478686B1 (en) 1989-06-22 1993-08-11 Applications Et Transferts De Technologies Avancees Atta Fluorine and phosphorous-containing amphiphilic molecules with surfactant properties
FR2649335B1 (fr) 1989-07-05 1991-09-20 Texinfine Sa Procede et dispositif de production directe de liposomes
US5019370A (en) 1989-07-10 1991-05-28 University Of Kentucky Research Foundation Biodegradable, low biological toxicity radiographic contrast medium and method of x-ray imaging
US5194266A (en) 1989-08-08 1993-03-16 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition and method
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
US5562608A (en) 1989-08-28 1996-10-08 Biopulmonics, Inc. Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation
AU650845B2 (en) 1989-08-28 1994-07-07 K. Michael Sekins Lung cancer hyperthermia via ultrasound and/or convection with perfluorocarbon liquids
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5620689A (en) 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
US5843473A (en) * 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
US5123414A (en) 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5230882A (en) 1989-12-22 1993-07-27 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5149319A (en) 1990-09-11 1992-09-22 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5773024A (en) * 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5352435A (en) 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5088499A (en) * 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US6001335A (en) 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US6551576B1 (en) * 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5334381A (en) * 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5209720A (en) 1989-12-22 1993-05-11 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes
US5922304A (en) * 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5656211A (en) * 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5228446A (en) * 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5776429A (en) * 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US5741513A (en) * 1990-02-08 1998-04-21 A. Natterman & Cie. Gmbh Alcoholic aqueous gel-like phospholipid composition, its use and topical preparations containing it
DE4004430A1 (de) 1990-02-09 1991-08-14 Schering Ag Aus polyaldehyden aufgebaute kontrastmittel
GB9003821D0 (en) 1990-02-20 1990-04-18 Danbiosyst Uk Diagnostic aid
US5578292A (en) 1991-11-20 1996-11-26 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US5556610A (en) 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
IN172208B (zh) 1990-04-02 1993-05-01 Sint Sa
US5279833A (en) * 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5672585A (en) 1990-04-06 1997-09-30 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5368840A (en) 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
JPH05506227A (ja) 1990-04-10 1993-09-16 イマルクス　ファーマシューティカル　コーポレーション 磁気共鳴画像用造影剤としてのポリマー
US5358702A (en) 1990-04-10 1994-10-25 Unger Evan C Methoxylated gel particle contrast media for improved diagnostic imaging
US5078994A (en) 1990-04-12 1992-01-07 Eastman Kodak Company Microgel drug delivery system
JPH03297475A (ja) 1990-04-16 1991-12-27 Ken Ishihara 共振音波により薬物の放出を制御する方法
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5190982A (en) 1990-04-26 1993-03-02 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5205287A (en) * 1990-04-26 1993-04-27 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
US5137928A (en) 1990-04-26 1992-08-11 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
WO1991018612A1 (en) 1990-06-01 1991-12-12 Unger Evan C Contrast media for ultrasonic imaging
US5196348A (en) 1990-06-11 1993-03-23 Air Products And Chemicals, Inc. Perfluoro-crown ethers in fluorine magnetic resonance spectroscopy of biopsied tissue
US5315997A (en) 1990-06-19 1994-05-31 Molecular Biosystems, Inc. Method of magnetic resonance imaging using diamagnetic contrast
US5215680A (en) 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
IL95743A (en) 1990-09-19 1993-02-21 Univ Ramot Method of measuring blood flow
US5487390A (en) 1990-10-05 1996-01-30 Massachusetts Institute Of Technology Gas-filled polymeric microbubbles for ultrasound imaging
CA2068334C (en) 1990-10-05 1996-09-03 Claude Giddey Method for the preparation of stable suspensions of hollow gas-filled microspheres suitable for ultrasonic echography
IS1685B (is) 1990-12-11 1998-02-24 Bracco International B.V. Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum
CA2098849C (en) 1990-12-20 2007-07-10 Ralph R. Weichselbaum Control of gene expression by ionizing radiation
DE4100470A1 (de) 1991-01-09 1992-07-16 Byk Gulden Lomberg Chem Fab Echokontrastmittel
US5193237A (en) * 1991-01-28 1993-03-16 Holdredge Terry K Pneumatic wheel chair cushion for reducing ischemic injury
US5107842A (en) 1991-02-22 1992-04-28 Molecular Biosystems, Inc. Method of ultrasound imaging of the gastrointestinal tract
EP0732106A3 (en) 1991-03-22 2003-04-09 Katsuro Tachibana Microbubbles containing booster for therapy of disease with ultrasound
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
ES2082459T3 (es) 1991-03-28 1996-03-16 Nycomed Imaging As Agente reticulante.
GB9106686D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
US5874062A (en) 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5205290A (en) * 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5496535A (en) 1991-04-12 1996-03-05 Alliance Pharmaceutical Corp. Fluorocarbon contrast media for use with MRI and radiographic imaging
US5147631A (en) 1991-04-30 1992-09-15 Du Pont Merck Pharmaceutical Company Porous inorganic ultrasound contrast agents
ATE151992T1 (de) 1991-06-03 1997-05-15 Nycomed Imaging As Verbesserungen im bezug auf kontrastmittel
JP2868335B2 (ja) 1991-06-13 1999-03-10 富士通株式会社 交換機及び交換機における切断通知方法
AU667672B2 (en) 1991-06-18 1996-04-04 Imarx Therapeutics, Inc. Novel liposomal drug delivery systems
AU675050B2 (en) * 1991-07-05 1997-01-23 Nycomed Imaging As Improvements in or relating to contrast agents
EP0593627A1 (en) 1991-07-05 1994-04-27 The University Of Rochester Ultrasmall non-aggregated porous particles entrapping gas-bubbles
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US5283185A (en) * 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5409688A (en) 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
RU2114637C1 (ru) 1991-09-17 1998-07-10 Сонус Фармасьютикалз, Инк. Биосовместимая контрастная среда и способ получения ультразвукового изображения
MX9205298A (es) 1991-09-17 1993-05-01 Steven Carl Quay Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
AU2789192A (en) 1991-10-04 1993-05-03 Mallinckrodt Medical, Inc. Gaseous ultrasound contrast agents
US5362477A (en) 1991-10-25 1994-11-08 Mallinckrodt Medical, Inc. 19F magnetic resonance imaging agents which include a nitroxide moiety
US5264220A (en) 1991-11-12 1993-11-23 Long David M Jr Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents
US5196183A (en) 1991-12-04 1993-03-23 Sterling Winthrop Inc. Contrast agents for ultrasound imaging
US5403575A (en) 1991-12-12 1995-04-04 Hemagen/Pfc Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of using them
GB9200391D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200387D0 (en) * 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200388D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
JP3325300B2 (ja) 1992-02-28 2002-09-17 株式会社東芝 超音波治療装置
RU2122432C1 (ru) 1992-03-06 1998-11-27 Нюкомед Имагинг АС Контрастные агенты и их применение
US5247935A (en) 1992-03-19 1993-09-28 General Electric Company Magnetic resonance guided focussed ultrasound surgery
WO1993020802A1 (en) 1992-04-09 1993-10-28 Northwestern University Acoustically reflective liposomes and methods to make and use the same
US5858399A (en) 1992-04-09 1999-01-12 Northwestern University Acoustically reflective liposomes and methods to make and use the same
US5339814A (en) 1992-04-14 1994-08-23 Lasker Sigmund E Process for visualizing tissue metabolism using oxygen-17
US5846516A (en) 1992-06-03 1998-12-08 Alliance Pharmaceutial Corp. Perfluoroalkylated amphiphilic phosphorus compounds: preparation and biomedical applications
DE4221256C2 (de) 1992-06-26 1997-07-10 Lancaster Group Ag Galenische Zusammensetzung für die topische Anwendung
US5334761A (en) * 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
EP0835664A3 (en) 1992-09-16 1998-08-12 Nycomed As Improvements in or relating to contrast agents
DE4232755A1 (de) 1992-09-26 1994-03-31 Schering Ag Mikropartikelpräparationen aus biologisch abbaubaren Mischpolymeren
US5552155A (en) 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5558855A (en) 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
SG52198A1 (en) 1993-01-25 1998-09-28 Sonus Pharma Inc Phase shift colloids as ultrasound contrast agents
FR2700952B1 (fr) 1993-01-29 1995-03-17 Oreal Nouvelles compositions cosmétiques ou dermopharmaceutiques sous forme de gels aqueux modifiés par addition de microsphères expansées.
SE501697C2 (sv) * 1993-02-11 1995-04-24 Svenska Mejeriernas Riksforeni Förfarande för utvinning av sfingomyelin
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
CA2155947C (en) 1993-02-22 2007-08-21 Mark W. Grinstaff Methods for in vivo delivery of biologics and compositions useful therefor
JPH06247842A (ja) * 1993-02-23 1994-09-06 Green Cross Corp:The リポソーム組成物の製造方法
WO1994021303A1 (en) 1993-03-16 1994-09-29 Alliance Pharmaceutical Corp. Fluorocarbon compositions containing a visible or fluorescent label
GB9305349D0 (en) 1993-03-16 1993-05-05 Nycomed Imaging As Improvements in or relating to contrast agents
GB9305351D0 (en) 1993-03-16 1993-05-05 Nycomed Imaging As Improvements in or relating to contrast agents
DE4313402A1 (de) * 1993-04-23 1994-10-27 Hexal Pharma Gmbh Transdermale Wirkstoffzubereitung
US5567415A (en) 1993-05-12 1996-10-22 The Board Of Regents Of The University Of Nebraska Ultrasound contrast agents and methods for their manufacture and use
US5701899A (en) 1993-05-12 1997-12-30 The Board Of Regents Of The University Of Nebraska Perfluorobutane ultrasound contrast agent and methods for its manufacture and use
US5716597A (en) 1993-06-04 1998-02-10 Molecular Biosystems, Inc. Emulsions as contrast agents and method of use
US5855865A (en) 1993-07-02 1999-01-05 Molecular Biosystems, Inc. Method for making encapsulated gas microspheres from heat denatured protein in the absence of oxygen gas
WO1995001187A1 (en) 1993-07-02 1995-01-12 Molecular Biosystems, Inc. Protein encapsulated insoluble gas microspheres and their preparation and use as ultrasonic imaging agents
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5853755A (en) * 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
US5798091A (en) * 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
EP1550464A1 (en) 1993-07-30 2005-07-06 IMCOR Pharmaceutical Co. Stabilized microbubble composition for ultrasound
GB9318288D0 (en) 1993-09-03 1993-10-20 Nycomed Imaging As Improvements in or relating to contrast agents
AU7655194A (en) 1993-09-09 1995-03-27 Schering Aktiengesellschaft Active principles and gas containing microparticles
ATE164515T1 (de) 1993-11-05 1998-04-15 Amgen Inc Herstellung von liposomen und verfahren zur substanzverkapselung
US5433204A (en) 1993-11-16 1995-07-18 Camilla Olson Method of assessing placentation
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
PL182223B1 (pl) 1993-12-15 2001-11-30 Bracco Research Sa Biokompatybilna faza rozproszona do otrzymywania srodka kontrastowego do badan ultradzwiekowych, srodek kontrastowy do badan ultradzwiekowych, suchy preparat srodka kontrastowego oraz dwuskladnikowy zestaw do otrzymywania srodka kontrastowego do badan ultradzwiekowych PL PL PL
NO940711D0 (no) 1994-03-01 1994-03-01 Nycomed Imaging As Preparation of gas-filled microcapsules and contrasts agents for diagnostic imaging
KR970701551A (ko) * 1994-03-11 1997-04-12 고야 마사시 리포좀 제제(liposome preparation)
US5667472A (en) 1994-03-18 1997-09-16 Clarus Medical Systems, Inc. Surgical instrument and method for use with a viewing system
CN1148812A (zh) 1994-03-28 1997-04-30 尼科梅德成像有限公司 “脂质体”
US5545396A (en) 1994-04-08 1996-08-13 The Research Foundation Of State University Of New York Magnetic resonance imaging using hyperpolarized noble gases
CA2189366A1 (en) 1994-05-03 1995-11-09 Kenneth J. Widder Composition for ultrasonically quantitating myocardial perfusion
US5571797A (en) 1994-05-11 1996-11-05 Arch Development Corporation Method of inducing gene expression by ionizing radiation
US5502094A (en) 1994-05-20 1996-03-26 Minnesota Mining And Manufacturing Company Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use
US5736121A (en) 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
US5571498A (en) 1994-06-02 1996-11-05 Hemagen/Pfc Emulsions of paramagnetic contrast agents for magnetic resonance imaging (MRI).
AU2925195A (en) * 1994-07-07 1996-02-09 Bayer Aktiengesellschaft 2-aryl cyclopentane-1,3-dione derivatives
US6066331A (en) * 1994-07-08 2000-05-23 Barenholz; Yechezkel Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers
US6159445A (en) 1994-07-20 2000-12-12 Nycomed Imaging As Light imaging contrast agents
US5965109A (en) * 1994-08-02 1999-10-12 Molecular Biosystems, Inc. Process for making insoluble gas-filled microspheres containing a liquid hydrophobic barrier
US5562893A (en) 1994-08-02 1996-10-08 Molecular Biosystems, Inc. Gas-filled microspheres with fluorine-containing shells
US5509896A (en) 1994-09-09 1996-04-23 Coraje, Inc. Enhancement of thrombolysis with external ultrasound
US6113570A (en) * 1994-09-09 2000-09-05 Coraje, Inc. Method of removing thrombosis in fistulae
JPH08151335A (ja) 1994-09-27 1996-06-11 Otsuka Pharmaceut Co Ltd 超音波造影剤およびその製造方法
US5540909A (en) 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
AU3559695A (en) * 1994-09-30 1996-04-26 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
EP0727225A3 (en) 1995-02-14 1997-01-15 Sonus Pharma Inc Compositions and methods for directed ultrasonic imaging
US5556372A (en) 1995-02-15 1996-09-17 Exogen, Inc. Apparatus for ultrasonic bone treatment
US5830430A (en) 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5560364A (en) 1995-05-12 1996-10-01 The Board Of Regents Of The University Of Nebraska Suspended ultra-sound induced microbubble cavitation imaging
AU5739196A (en) 1995-05-15 1996-11-29 Coraje, Inc. Enhancement of ultrasound thrombolysis
US5558092A (en) 1995-06-06 1996-09-24 Imarx Pharmaceutical Corp. Methods and apparatus for performing diagnostic and therapeutic ultrasound simultaneously
US5997898A (en) 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US5897851A (en) 1995-06-07 1999-04-27 Sonus Pharmaceuticals, Inc. Nucleation and activation of a liquid-in-liquid emulsion for use in ultrasound imaging
US6231834B1 (en) * 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6033645A (en) 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
WO1996040285A1 (en) * 1995-06-07 1996-12-19 Imarx Pharmaceutical Corp. Novel targeted compositions for diagnostic and therapeutic use
US5606973A (en) 1995-06-07 1997-03-04 Molecular Biosystems, Inc. Liquid core microdroplets for ultrasound imaging
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US5780010A (en) 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
US5958371A (en) 1995-06-08 1999-09-28 Barnes-Jewish Hospital Site specific binding system, nuclear imaging compositions and methods
US6120794A (en) * 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US5648098A (en) 1995-10-17 1997-07-15 The Board Of Regents Of The University Of Nebraska Thrombolytic agents and methods of treatment for thrombosis
US5840023A (en) 1996-01-31 1998-11-24 Oraevsky; Alexander A. Optoacoustic imaging for medical diagnosis
US6165442A (en) * 1996-02-19 2000-12-26 Nycomed Imaging As Thermally stabilized ultrasound contrast agent
US5879659A (en) * 1996-03-13 1999-03-09 Dupont Pharmaceuticals Company Ternary radiopharmaceutical complexes
US6455277B1 (en) * 1996-04-22 2002-09-24 Amgen Inc. Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
AU736301B2 (en) 1996-05-01 2001-07-26 Imarx Therapeutics, Inc. Methods for delivering compounds into a cell
US5976501A (en) 1996-06-07 1999-11-02 Molecular Biosystems, Inc. Use of pressure resistant protein microspheres encapsulating gases as ultrasonic imaging agents for vascular perfusion
US5849727A (en) 1996-06-28 1998-12-15 Board Of Regents Of The University Of Nebraska Compositions and methods for altering the biodistribution of biological agents
US6214375B1 (en) 1996-07-16 2001-04-10 Generex Pharmaceuticals, Inc. Phospholipid formulations
US5837221A (en) 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
ES2189974T3 (es) * 1996-09-11 2003-07-16 Imarx Pharmaceutical Corp Procedimientos mejorados para la obtencion de imagenes de diagnostico usando un agente de contraste y un vasodilatador.
HU224218B1 (hu) 1996-10-21 2005-06-28 Amersham Health As Továbbfejlesztett kontrasztanyagok
CN1238700A (zh) 1996-10-28 1999-12-15 奈科姆成像有限公司 诊断和/或治疗剂的改进或与其相关的改进
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
WO1998018495A2 (en) 1996-10-28 1998-05-07 Marsden, John, Christopher Improvements in or relating to diagnostic/therapeutic agents
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
EP0973552B1 (en) 1996-10-28 2006-03-01 Amersham Health AS Improvements in or relating to diagnostic/therapeutic agents
EP0963209A2 (en) 1996-10-28 1999-12-15 Marsden, John Christopher Improvements in or relating to diagnostic/therapeutic agents
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6537246B1 (en) * 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
JP2001524958A (ja) * 1997-04-17 2001-12-04 ジーエス ディベロップメント アクティエボラーグ 新規な液晶をベースとする生物接着性薬剤送出系
AU6974798A (en) 1997-05-06 1998-11-27 Imarx Pharmaceutical Corp. Novel prodrugs comprising fluorinated amphiphiles
US6416740B1 (en) * 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
GB9717588D0 (en) 1997-08-19 1997-10-22 Nycomed Imaging As Improvements in or relating to contrast agents
US6548047B1 (en) * 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
ES2244169T3 (es) 1998-02-09 2005-12-01 Bracco International B.V. Suministro direccionado de medios biologicamente activos.
US6261231B1 (en) * 1998-09-22 2001-07-17 Dupont Pharmaceuticals Company Hands-free ultrasound probe holder
US6398772B1 (en) * 1999-03-26 2002-06-04 Coraje, Inc. Method and apparatus for emergency treatment of patients experiencing a thrombotic vascular occlusion
US6254852B1 (en) * 1999-07-16 2001-07-03 Dupont Pharmaceuticals Company Porous inorganic targeted ultrasound contrast agents
US6572840B1 (en) * 1999-07-28 2003-06-03 Bristol-Myers Squibb Pharma Company Stable microbubbles comprised of a perfluoropropane encapsulated lipid moiety for use as an ultrasound contrast agent
GB9920392D0 (en) 1999-08-27 1999-11-03 Nycomed Imaging As Improvemets in or relating to diagnostic imaging
US6635017B1 (en) * 2000-02-09 2003-10-21 Spentech, Inc. Method and apparatus combining diagnostic ultrasound with therapeutic ultrasound to enhance thrombolysis
US6943692B2 (en) * 2001-02-02 2005-09-13 Bristol-Myers Squibb Pharma Company Apparatus and methods for on-line monitoring of fluorinated material in headspace of vial
BR0307206A (pt) * 2002-01-24 2004-12-21 Barnes Jewish Hospital Agentes de formação de imagem direcionados por integrina
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US10279053B2 (en) 2011-07-19 2019-05-07 Nuvox Pharma Llc Microbubble compositions, method of making same, and method using same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1321697C (zh) * 2003-12-23 2007-06-20 中国人民解放军军事医学科学院毒物药物研究所 一种以磷脂类成分为成膜材料的超声造影剂组合物及其制备方法

Also Published As

Publication number Publication date
AU2115599A (en) 1999-08-02
US20040057991A1 (en) 2004-03-25
CN1191822C (zh) 2005-03-09
US8658205B2 (en) 2014-02-25
PL342473A1 (en) 2001-06-04
MY137255A (en) 2009-01-30
US20120128595A1 (en) 2012-05-24
CA2317921A1 (en) 1999-07-22
UA75023C2 (en) 2006-03-15
JP5160702B2 (ja) 2013-03-13
ATE447976T1 (de) 2009-11-15
NO321866B1 (no) 2006-07-17
ZA99247B (en) 2000-07-14
KR20010034106A (ko) 2001-04-25
US20150023880A1 (en) 2015-01-22
PT1419789E (pt) 2010-02-17
JP2012211184A (ja) 2012-11-01
WO1999036104A2 (en) 1999-07-22
WO1999036104A3 (en) 2000-01-13
BR9907066A (pt) 2001-09-04
KR100711663B1 (ko) 2007-04-27
EP1419789A2 (en) 2004-05-19
EP1419789A3 (en) 2004-05-26
HUP0100206A3 (en) 2011-04-28
NO20003471D0 (no) 2000-07-05
EE04900B1 (et) 2007-10-15
SK10312000A3 (sk) 2000-11-07
AR016444A1 (es) 2001-07-04
AU746067C (en) 2003-06-05
US20120027688A1 (en) 2012-02-02
HRP990012A2 (en) 1999-10-31
US8685441B2 (en) 2014-04-01
ES2336669T3 (es) 2010-04-15
EP1027035A2 (en) 2000-08-16
AU746067B2 (en) 2002-04-11
SI1419789T1 (sl) 2010-03-31
TWI242448B (en) 2005-11-01
JP2002509121A (ja) 2002-03-26
HK1064301A1 (en) 2005-01-28
CA2317921C (en) 2011-03-22
EP1419789B1 (en) 2009-11-11
NZ505082A (en) 2002-11-26
IL137018A0 (en) 2001-06-14
NO20003471L (no) 2000-08-29
SK285333B6 (sk) 2006-11-03
EA002978B1 (ru) 2002-12-26
PH12012000094A1 (en) 2016-07-04
US8084056B2 (en) 2011-12-27
US20170312375A1 (en) 2017-11-02
US9545457B2 (en) 2017-01-17
DE69941634D1 (de) 2009-12-24
US8747892B2 (en) 2014-06-10
US20130309174A1 (en) 2013-11-21
US20010003580A1 (en) 2001-06-14
DK1419789T3 (da) 2010-03-29
IL137018A (en) 2013-10-31
PL193672B1 (pl) 2007-03-30
HUP0100206A2 (hu) 2001-06-28
EE200000422A (et) 2001-12-17
US20130309175A1 (en) 2013-11-21
EA200000765A1 (ru) 2000-12-25

Similar Documents

Publication Publication Date Title
CN1191822C (zh) 脂质混合物以及含该脂质混合物的磷脂悬浮物的制备
CN1191093C (zh) Dds化合物及其测定方法
CN1505503A (zh) 亚微米颗粒悬浮液制备方法
CN1426433A (zh) 用于制备微球的方法
CN1523961A (zh) 油料种子蛋白质分离物的生产
CN1798796A (zh) 纤维素粉末
CN87105547A (zh) 单个双层的脂质体的制备方法
CN1802150A (zh) 载体颗粒
CN1603232A (zh) 介孔二氧化硅颗粒及其生产方法
CN1814305A (zh) 载基因或药物的超声微泡造影剂及其制备方法
CN1780609A (zh) 将水溶性或亲水物质分散在超临界压力下的流体中的方法
CN1209099C (zh) 结晶化附聚物
CN1761457A (zh) 三水羟氨苄青霉素
CN1596270A (zh) 具有高甘露糖醛酸含量的藻酸盐的制备方法
CN1927206A (zh) 氯诺昔康注射用组合物及其制备方法
CN1026014C (zh) 淀粉酶的分离精制方法，所用的吸附剂及分离精制装置
CN1680387A (zh) 羟基苯丙酸酯的制备方法
AU2006200015B8 (en) Preparation of a lipid blend and a phospholipid suspension containing a lipid blend, and contrast agents based on these
CN1761456A (zh) 三水羟氨苄青霉素结晶粉末
CN115353625A (zh) 一种高沸水解物制备混合烷基聚硅氧烷的方法
CN1634064A (zh) 伊曲康唑结构化乳剂组合物及其制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20050309

CX01 Expiry of patent term